CagriSema vs. Retatrutide: How These Next-Generation Weight-Loss Drugs Differ
CagriSema and retatrutide are increasingly mentioned in the same conversation because both represent what may come next after today’s best-known weight-management medications. Biologically, though, they are very different ideas.
The simplest way I think about them is this: CagriSema combines two complementary satiety pathways, while retatrutide builds three receptor targets into one molecule.
CagriSema: GLP-1 + amylin
CagriSema combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analogue.
GLP-1 is already familiar in weight management. Amylin is less familiar, but it is a normal hormone involved in meal-related satiety. The combination is designed to influence appetite and fullness through two different biological systems.
In REDEFINE 1, CagriSema produced 20.4% average weight reduction at 68 weeks in the treatment-policy analysis and 22.7% in the analysis estimating the effect if participants remained on treatment.
Retatrutide: GIP + GLP-1 + glucagon
Retatrutide is a single molecule that activates GIP, GLP-1, and glucagon receptors.
The glucagon component is what makes the concept especially different. Researchers are studying whether adding that pathway can influence energy balance and fuel metabolism in addition to the appetite and metabolic effects associated with incretin signaling.
In TRIUMPH-1, the 12 mg dose produced 28.3% average weight reduction at 80 weeks. Lilly has since reported positive topline results from additional Phase 3 studies, including TRIUMPH-2 in adults with type 2 diabetes and TRIUMPH-3 in adults with severe obesity and established cardiovascular disease.
Can we simply compare the percentages?
Not directly. These numbers come from different trials, different protocols, different treatment durations, and different participant groups. They help us understand the magnitude of the results, but they are not a head-to-head test of CagriSema versus retatrutide.
What I find more useful is the biology. CagriSema asks what happens when we pair GLP-1 with amylin. Retatrutide asks what happens when we combine GIP, GLP-1, and glucagon in one molecule. Those are two genuinely different strategies.
The FDA timelines are different too
As of October 2026, CagriSema is further along in the U.S. process. Novo Nordisk submitted the NDA in December 2025 and says a U.S. decision is expected in the fourth quarter of 2026.
Lilly says it plans to submit retatrutide to the FDA in the first quarter of 2027 after completing the clinical and manufacturing package supporting its application.
The bigger picture
The future of obesity medicine may not be about finding one universally “best” hormone pathway. It may be about having enough different tools to match treatment more intelligently to the person in front of us.
That is why I am following both medications. They are not simply two competitors chasing the same idea. They may be previews of two different branches of the next generation of treatment.
Comments